Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Free Cash Flow data on record, last reported at $4.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 165.38% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $121.2 million, down 29.66%, while the annual FY2025 figure was $121.2 million, 29.66% down from the prior year.
  • Free Cash Flow reached $4.5 million in Q4 2025 per AMPH's latest filing, down from $67.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $71.2 million in Q2 2024 and bottomed at -$11.0 million in Q3 2021.
  • Average Free Cash Flow over 5 years is $31.4 million, with a median of $30.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: crashed 191.52% in 2021, then surged 1880.87% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $33.6 million in 2021, then plummeted by 60.07% to $13.4 million in 2022, then soared by 78.39% to $23.9 million in 2023, then tumbled by 128.85% to -$6.9 million in 2024, then surged by 165.38% to $4.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $4.5 million in Q4 2025, $67.3 million in Q3 2025, and $25.0 million in Q2 2025.